In this issue:
Inclusion of daratumumab in front-line induction triplets is cost effective
Limited efficacy of daratumumab for patients with extramedullary RRMM
Elucidation of optimal lenalidomide-sparing regimens in the RR setting
MRD surveillance is a feasible alternative to indefinite maintenance
MRD status after ASCT is prognostic for outcome
MajesTEC-1: Teclistamab elicits deep and durable responses in RRMM
Survival and outcomes of newly diagnosed myeloma in Canada 2007-2018
Predictors of early mortality in myeloma
Genomic analysis of RRMM finds a complex mutational landscape
Novel triplet MAPK inhibition for BRAF V600E mutated RR disease
Please login below to download this issue (PDF)